March 4, 2020 – By going commercial, DNA Encoded Library (DEL) technology facilitates rapid discovery and provides access to more chemical entities at lower cost. Over the years, DEL has become a disruptive drug discovery technology in comparison to traditional high-throughput screening (HTS) where it allows expedition of early stage drug discovery. However, DEL platforms don’t succeed …Read More >

Summary Traditional small molecule therapeutic mechanisms have recently been augmented by a new strategy to specifically manipulate the levels of disease-related proteins. By employing bifunctional molecules, we can hijack endogenous cellular degradation mechanism for targeted degradation of a disease-related protein. Bifunctional molecules consisting of a ligand that binds to an E3 ligase, connected by a …Read More >

Activating KRAS mutations, including G12C and G12D, are detected in approximately 25% of human cancers. The most common KRAS mutation is G12C, which comprises nearly 15% of lung adenocarcinomas, 8% of colorectal carcinomas and 4% of pancreatic adenocarcinomas. AMG-510 from Amgen and MRTX849 from Mirati Therapeutics, both targeting the KRASG12C mutant, have shown encouraging results …Read More >

Magical Power of Quantum Mechanics EBook Would you like to predict organic reaction outcomes accurately? Design synthetic sequences with higher rate of success? Would you prefer to learn and rationalize organic chemistry in a data-driven manner? Quantum Mechanics (QM) and artificial intelligence tools for chemistry are evolving at a tremendously fast pace and have proven to …Read More >

Integrated Services BIOLOGY & PHARMACOLOGY BINARY/TERNARY COMPLEX FORMATION Biochemical & Biophysical Assays Biochemical binding assay Cellular Assays TARGET UBIQUITINATION & DEGRADATION In vitro Assays-Target ubiquitination Target degradation assay PK/PD Animal Disease Model Evaluation CHEMISTRY Specific virtual library design Compound synthesis Conjugation and all type of custom syntheses from milligram to kilogram scale Purification and analytical …Read More >

Integrated Drug Discovery Platform for Antibody & Protein Preparation We are dedicated to offering an integrated and cost-effective services platform of polyclonal and monoclonal antibodies, including: Antigen design and preparation Anti-drug antibodies (ADA) Host cell protein (HCP) antibodies Surrogate antibodies Diagnostic antibodies Therapeutic antibodies Learn about our services platform for evaluating bispecific antibodies

WuXi AppTec  provides a one-stop solution for DEL services from target to hit series. Our extended platform enables overall planning and management of protein production, DEL library production, affinity selection, data analysis, hit validation and structural biology for further optimization.